Rapidly delivering diverse biotherapeutics to patients requires efficiently developing innovative, robust manufacturing processes and technologies. Successful bioprocess development organizations must simultaneously optimize for speed to clinic, speed to launch, robust supply and low cost. Flexible manufacturing platforms that are robust across diverse modalities are foundational. State of the art platforms are highly productive and deployable in reconfigurable facilities that facilitate rapid, cost effective capacity scaling. Such platforms increasingly rely upon intensified and continuous manufacturing technologies. This talk will review enabling technologies and strategies for evolving legacy manufacturing platforms.

Next generation bioprocess development

Macromolecular Chemistry: The Second Century

[Author Benefits](https://scimeetings.acs.org/?utm_source=pubs_content_marketing&utm_medium=website&utm_campaign=0320_MCF_NPI_Launch_Spring_Homepage&ref=pubs_content_marketing)

[How to use SciMeetings](https://storage.googleapis.com/dl.morressier.com/acs/SciMeetings-ACSSpring2020-HowToGuide_M3020-Final.pdf)

[Frequently Asked Questions](https://storage.googleapis.com/dl.morressier.com/acs/SciMtng_ACSNMSp2020_FAQ_M3120_Final.pdf)

ACS Spring 2020 National Meeting & Expo

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.